Company: STAA
Filing Date: 2025-08-05
Form Type: DEFA14A
Source: 0001193125-25-173098
Chunk: 128

Company: STAAR SURGICAL CO
Filing Date: 2025-08-05
Form: DEFA14A
Chunk 128
---
” is defined
in of the Agreement.

Willful Breach. “” is defined in
of the Agreement.

Window Shop End Time. “” means 11:59
p.m. (New York time) on September 19, 2025.

A-17

Exhibit 99.1 Alcon Agrees to Acquire STAAR Surgical

| • |     | STAAR Surgical is a leader in refractive surgery using Implantable Collamer Lenses, offering solutions for 
 moderate to high myopes                                                                                    |

| • |     | Acquisition of STAAR is complementary to Alcon’s laser vision correction business and is expected to be 
 accretive in year two                                                                                   |

| • |     | Alcon to purchase all outstanding shares of STAAR for $28 per share in cash, valuing STAAR at approximately 
 $1.5 billion in equity value                                                                                |

Ad Hoc Announcement Pursuant to Art. 53 LR GENEVA and LAKE FOREST, CA, Aug 5, 2025 –Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, and STAAR Surgical Company (NASDAQ: STAA), the manufacturer of the Implantable Collamer ®Lens (ICL), today announced the companies have entered into a definitive merger agreement through which Alcon intends to acquire STAAR. The acquisition includes the EVO family of lenses (EVO ICL ™) for vision correction for patients with moderate to high myopia (nearsightedness), with or without astigmatism. Under the terms of the agreement, Alcon will purchase all outstanding shares of STAAR common stock for $28 per share in cash, which represents approximately a 59% premium to STAAR’s 90-dayVolume Weighted Average Price (VWAP) and a 51% premium to the closing price of STAAR common stock on August 4, 2025. The transaction represents a total equity value of approximately $1.5 billion. “With the number of high myopes rising globally, the acquisition of STAAR enhances our ability to offer a leading surgical vision correction solution for those who are not ideal candidates for other refractive surgeries such as LASIK,” said David Endicott, CEO of Alcon. “This transaction will allow us to provide treatment options across the full spectrum of myopia—from contact lenses to surgical interventions—reinforcing our commitment to addressing the most significant needs in eye care